About halozyme therapeutics inc. - HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
HALO At a Glance
Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, California 92130
| Phone | 1-858-794-8889 | Revenue | 1.40B | |
| Industry | Biotechnology | Net Income | 316.89M | |
| Sector | Health Technology | 2025 Sales Growth | 37.553% | |
| Fiscal Year-end | 12 / 2026 | Employees | 423 | |
| View SEC Filings |
HALO Valuation
| P/E Current | 25.271 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 26.315 |
| Price to Sales Ratio | 5.971 |
| Price to Book Ratio | 162.388 |
| Price to Cash Flow Ratio | 12.80 |
| Enterprise Value to EBITDA | 11.47 |
| Enterprise Value to Sales | 7.427 |
| Total Debt to Enterprise Value | 0.21 |
HALO Efficiency
| Revenue/Employee | 3,301,680.851 |
| Income Per Employee | 749,146.572 |
| Receivables Turnover | 3.165 |
| Total Asset Turnover | 0.573 |
HALO Liquidity
| Current Ratio | 4.66 |
| Quick Ratio | 3.663 |
| Cash Ratio | 0.806 |
HALO Profitability
| Gross Margin | 78.13 |
| Operating Margin | 58.448 |
| Pretax Margin | 33.429 |
| Net Margin | 22.69 |
| Return on Assets | 12.992 |
| Return on Equity | 153.593 |
| Return on Total Capital | 14.236 |
| Return on Invested Capital | 15.428 |
HALO Capital Structure
| Total Debt to Total Equity | 4,460.194 |
| Total Debt to Total Capital | 97.807 |
| Total Debt to Total Assets | 80.212 |
| Long-Term Debt to Equity | 4,437.092 |
| Long-Term Debt to Total Capital | 97.301 |